#biotech
Total 3 articles
ViralEN
Biological Black Swans: Why 'Fake' Sounding Diseases Are a Biotech Goldmine
Discover why rare medical conditions are not just curiosities, but a biotech goldmine driving the future of gene editing, neurotech, and personalized medicine.
EconomyEN
The $1B Drug: How China is Engineering the End of Big Pharma's R&D Empire
China is no longer a pharma copycat. With $1B R&D cycles and a massive data advantage, it's building a new global innovation engine. A PRISM analysis for investors.
TechEN
The OpenAI Mafia Invades Pharma: Why Chai Discovery's $1.3B Bet is Reshaping Drug Discovery
Chai Discovery's $130M raise at a $1.3B valuation isn't a funding story. It's a signal that elite AI talent is targeting pharma's core business model.